Compare CLW & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | VNDA |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 289.0M |
| IPO Year | N/A | 2006 |
| Metric | CLW | VNDA |
|---|---|---|
| Price | $17.90 | $6.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $30.00 | $14.00 |
| AVG Volume (30 Days) | 171.4K | ★ 1.3M |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 875.72 | N/A |
| EPS | ★ 8.63 | N/A |
| Revenue | ★ $1,556,100,000.00 | $212,074,000.00 |
| Revenue This Year | $13.91 | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | $2.07 | ★ N/A |
| Revenue Growth | ★ 23.00 | 11.12 |
| 52 Week Low | $16.44 | $3.81 |
| 52 Week High | $33.57 | $6.88 |
| Indicator | CLW | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 63.55 |
| Support Level | $17.47 | $4.89 |
| Resistance Level | $18.70 | $6.88 |
| Average True Range (ATR) | 0.61 | 0.39 |
| MACD | 0.10 | 0.16 |
| Stochastic Oscillator | 65.93 | 70.10 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.